BRIEF published on 05/13/2026 at 08:35, 6 days 21 hours ago Inventiva présente ses recherches sur le lanifibranor au EASL Congress 2026 Biopharmaceutique Inventiva MASH Lanifibranor EASL Congress 2026
BRIEF published on 05/13/2026 at 08:35, 6 days 21 hours ago Inventiva présentera des résumés au congrès EASL 2026 Recherche Biopharmaceutique Inventive Lanifibranor Traitement MASH Congrès EASL 2026
BRIEF published on 05/13/2026 at 08:35, 6 days 21 hours ago Inventiva to Present Abstracts at EASL Congress 2026 Biopharmaceutical Research Inventiva Lanifibranor MASH Treatment EASL Congress 2026
BRIEF published on 05/13/2026 at 08:35, 6 days 21 hours ago Inventiva presents its research on lanifibranor at the EASL Congress 2026 Biopharmaceutical Inventiva MASH Lanifibranor EASL Congress 2026
PRESS RELEASE published on 05/13/2026 at 08:30, 6 days 21 hours ago Inventiva to Present Abstracts at the EASL Congress 2026 Inventiva to present two abstracts at EASL Congress 2026 highlighting Lanifibranor's impact on MASH treatment. Lanifibranor, a pan-PPAR agonist, shows promising results in clinical trials Clinical Trials Inventiva Lanifibranor MASH Treatment EASL Congress 2026
PRESS RELEASE published on 05/13/2026 at 08:30, 6 days 21 hours ago Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026 Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026. Découvrez les détails des présentations et la présence de la société au congrès Biopharmaceutique Inventiva MASH Lanifibranor EASL Congress 2026
BRIEF published on 04/22/2026 at 22:05, 27 days 7 hours ago Inventiva strengthens its leadership for phase 3 of lanifibranor Appointment Biopharmaceutical Direction Phase 3 Lanifibranor
BRIEF published on 04/22/2026 at 22:05, 27 days 7 hours ago Inventiva renforce son équipe de direction à l'approche d'une étape clé de la phase 3. Essai De Phase 3 Lanifibranor Développement Du Leadership Traitement MASH Inventiva Biopharmaceutique
BRIEF published on 04/22/2026 at 22:05, 27 days 7 hours ago Inventiva renforce sa direction pour la phase 3 du lanifibranor Nomination Biopharmaceutique Direction Phase 3 Lanifibranor
BRIEF published on 04/22/2026 at 22:05, 27 days 7 hours ago Inventiva Bolsters Executive Team as It Nears Key Phase 3 Data Milestone Phase 3 Trial Lanifibranor Leadership Expansion MASH Treatment Inventiva Biopharmaceutical
Published on 05/20/2026 at 03:21, 2 hours 29 minutes ago Challenger Assays Extend New Open Pittable Mineralisation
Published on 05/20/2026 at 00:00, 5 hours 50 minutes ago Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program
Published on 05/19/2026 at 19:45, 10 hours 5 minutes ago Karbon-X and Evertrak Sign Letter of Intent to Advance Infrastructure-Linked Plastic Waste Reduction Credit Initiative
Published on 05/19/2026 at 16:47, 13 hours 3 minutes ago Lithium South Re-Schedules Plan of Arrangement Closing as a Result of Cease Trade Order
Published on 05/19/2026 at 15:15, 14 hours 35 minutes ago Loop Industries Secures Gujarat Government Alignment Supporting First Commercial Deployment and Multi-Phase India Expansion
Published on 05/19/2026 at 21:24, 8 hours 26 minutes ago EQS-Adhoc: ams OSRAM announces the successful pricing of EUR 1 billion 7.250% Senior Notes due 2032, supporting the path to positive Free Cash Flow from 2027 onwards
Published on 05/19/2026 at 19:50, 10 hours ago EQS-Adhoc: fox e-mobility AG: 3 convertible bonds issued
Published on 05/19/2026 at 19:40, 10 hours 10 minutes ago PRC-Saltillo Named to Forbes Accessibility 200 List
Published on 05/19/2026 at 19:05, 10 hours 45 minutes ago Casper Ruud Returns to Stockholm as Bybit EU Expands Across the Nordics
Published on 05/19/2026 at 18:56, 10 hours 54 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/19/2026 at 18:34, 11 hours 15 minutes ago Availability of preparatory documents for the annual general meeting to be held on June 9, 2026
Published on 05/19/2026 at 18:34, 11 hours 15 minutes ago Mise à disposition des documents préparatoires à l’assemblée générale annuelle mixte des actionnaires du 9 juin 2026
Published on 05/19/2026 at 18:30, 11 hours 20 minutes ago TERACT- Communiqué InVivo Group - Retrait obligatoire
